Trial Profile
A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 microg twice daily of Formoterol-HFA and 12 microg twice daily of Formoterol-DPI (Foradil/Aerolizer) in children with persistent asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Formoterol (Primary) ; Formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 31 Mar 2022 Status changed from recruiting to completed.
- 05 Nov 2010 New trial record.